CURRENT

EVIDENCE1

.
SHOULD
BE
0 7 YOUR GOAL

IF YOUR GOAL IS BETTER RESULTS,

1

nmol/L

ELIGARD is indicated for the palliative treatment of advanced prostate cancer.2 ELIGARD with over 10 years experience in the LHRH
(leutinising hormone-releasing hormone) therapy across all dose forms.2 *European Association of Urology recommends a more
appropriate castration level defined as <0.7 nmol/L but the castration level considered by the regulatory authorities is still 1.7 nmol/L.1

Rapid and sustained testosterone suppression3

Over 90% of patients achieving testosterone levels 0.7 nmol/L by 6 weeks and
maintained up to 48 weeks with all 4 doses of ELIGARD (1-, 3-, 4- and 6-month doses).
A unique Atrigel delivery system for improved pharmacokinetics4,5
vs. microsphere-delivered leuprolide acetate.

NurseCARE provides patients with support through their treatment journey.2

An injection service for follow-up patient convenience and support.
Exercise support program and access to the EliFIT community.
CAREpack handbook with information about prostate cancer and
treatment with ELIGARD and practical tools.
To enrol your patients into NurseCARE visit www.eligard.com.au

Visit the TOLMAR stand for further information.

PBS Information: Restricted Benefit
Locally advanced (stage C) or metastatic (stage D) carcinoma of the prostate.

PLEASE REVIEW FULL PRODUCT INFORMATION BEFORE PRESCRIBING.

Product Information is available on request from TOLMAR (1800 865 627).
Eligard Minimum Product Information: INDICATIONS: Palliative treatment of advanced prostate cancer. DOSAGE: One subcutaneous injection of Eligard every
one/three/four/six months. Do not inject in the arm. CONTRAINDICATIONS: Hypersensitivity to GnRH, GnRH agonist analogues or any excipients. Pregnancy (Category
D) and lactation. Paediatric patients. Previous orchiectomy. Sole treatment in patients with spinal cord compression or evidence of spinal metastases. PRECAUTIONS:
Increase in serum testosterone causing bone pain, neuropathy, haematuria, urinary tract obstruction, spinal cord compression or ureteral obstruction; metastatic vertebral
lesions, diabetes, cardiovascular disease, QT interval, convulsions; elderly. INTERACTIONS: No reports. ADVERSE EFFECTS: Flare phenomenon, skin reactions; malaise,
fatigue, dizziness, alopecia, pruritis, myalgia, arthralgia, atrophy, or pain of testes, decreased libido, gynaecomastia; nervous system disturbances, depression, hot flashes/
sweats; haematologic disorders; urinary disorders; gastrointestinal disorders; decreased bone density, cardiovascular disorders, pituitary apoplexy. Based on PI May 2016.
References: 1. Mottet N (chair) et al. Guidelines on Prostate Cancer. European Association of Urology. Update March 2015. 2. ELIGARD Approved Product
Information, May 2016. 3. Shore ND et al. BJU Int 2016 Mar 17; doi: 10.1111/bju.13482. [Epub ahead of print] 4.Perez-Marrero R and Tyler RC. Expert Opin
Pharmacother 2004;5:44757. 5. Berges R. Eur Urol Supp 2005;4:205.

Eligard is a registered trademark of TOLMAR Therapeutics, Inc. Full Product Information is available from: TOLMAR Australia Pty Ltd.
ABN 53 162 640 708. Level 2/20 Bridge St, Pymble, NSW 2073. Ph: 1800 TOLMAR (865 627). TOLHTSI210616.
Date of approval: August 2016. TOL0068.